Gentian Diagnostics (OB:GENT) presented its third-quarter 2025 results on October 23, showcasing continued strong performance in a growing diagnostics market. The company, which targets a $2.2 billion serviceable diagnostic segment with 5-10% annual growth, has maintained its positive trajectory with a focus on efficient diagnostics for better treatment decisions.
The medical technology company has established a solid track record of growth, achieving a 26% compound annual growth rate (CAGR) from 2019 to 2024, with revenues increasing from NOK 48 million to NOK 152 million during this period.
As shown in the following chart of Gentian’s growth trajectory and business overview:
Quarterly Performance Highlights
Gentian reported impressive financial results for Q3 2025, with sales reaching NOK 41.8 million, representing a 28% increase compared to Q3 2024 (31% organic growth). EBITDA improved significantly to NOK 8.4 million, up from NOK 5.0 million in the same period last year, while gross margin expanded to 56% from 52% in Q3 2024.
The company’s year-to-date 2025 performance shows sales of NOK 129.9 million, a 19% increase versus the same period in 2024, with EBITDA reaching NOK 24.1 million compared to NOK 16.5 million in the previous year.
The following slide provides a comprehensive overview of Q3 2025 highlights:
Gross margin has recovered from production issues experienced in Q2 2025, returning to the company’s target range of 55-60%. This recovery demonstrates the company’s ability to quickly address operational challenges.
As illustrated in this chart showing gross and EBITDA margin development:
Regional Sales Analysis
The most significant growth driver for Gentian in Q3 2025 was the US market, where sales surged to NOK 10.8 million compared to NOK 2.4 million in Q3 2024. However, this figure was positively impacted by a warehouse shift for one customer, contributing NOK 5.4 million to US sales in the quarter (with a corresponding decline for Europe).
Even accounting for this one-time effect, US sales have shown remarkable organic growth, with the company adding over 30 new customers in 2025. These new accounts contributed NOK 2.3 million, representing 10% of year-to-date US sales.
The following table provides a detailed breakdown of sales by geographic region and product category:
While European sales remained relatively stable at NOK 26.8 million (a 2% decline from Q3 2024), Asian sales grew by 42% to NOK 4.2 million. However, management noted caution regarding the Chinese market due to a recently implemented “unbundling” initiative, which could impact future growth prospects in the region.
Product Portfolio Performance
Gentian’s product portfolio showed mixed performance, with Cystatin C emerging as the standout performer. Sales of this kidney disease marker increased by 73% in Q3 2025 compared to Q3 2024, driven by strong performance in the US market.
The chart below illustrates the impressive growth trajectory of Cystatin C:
The fCAL® turbo product, used for inflammatory bowel disease diagnostics, achieved its second-highest quarterly sales at NOK 15.9 million, representing an 11% increase compared to Q3 2024. Year-to-date, fCAL® turbo sales have recovered from a dip during the spring and are now at NOK 43.5 million, up 1% compared to 2024.
Other products, including fPELA and cCRP, grew by 37% compared to Q3 2024, generating sales of NOK 7.0 million. Year-to-date sales in this category reached NOK 21.0 million, representing 34% growth versus 2024.
Strategic Initiatives & Outlook
Gentian continues to advance its R&D pipeline, with significant progress on its NT-proBNP project for heart failure diagnostics. The company is working to introduce this assay as a research-use-only product by the end of 2025, with full commercial launch targeted for Q4 2026.
The NT-proBNP market is estimated at $1.0 billion in 2025, with a projected CAGR of 7% from 2025 to 2033. Gentian’s approach aims to improve accuracy by developing a glycosylation-independent assay, potentially addressing limitations in current tests.
Additionally, an undisclosed development project for a major IVD company successfully entered the next development phase, moving from proof-of-concept to optimization. The company also continued feasibility work on a novel detection technology with potential to significantly expand sensitivity limits beyond conventional PETIA-based systems.
The following slide outlines Gentian’s key drivers for long-term growth:
Financial Position
Gentian maintains a solid financial position with a cash balance of NOK 86.6 million as of Q3 2025, representing an increase of NOK 6.3 million since December 31, 2024. The company has no interest-bearing debt and reported an equity ratio of 86.8%.
Capital expenditures were NOK 1.4 million in Q3 2025, down from NOK 2.7 million in Q3 2024, while free cash flow reached NOK 6.3 million compared to NOK 12.5 million in the same period last year.
The company’s strong financial foundation supports its growth strategy, including ongoing R&D investments and potential market expansion opportunities. Gentian paid a dividend of NOK 6.2 million in Q2 2025, demonstrating its commitment to shareholder returns.
As of October 23, 2025, Gentian Diagnostics’ stock price remained unchanged at NOK 55, with a market capitalization of approximately $59.73 million. According to market analysis, the company trades at relatively high EBIT and EBITDA multiples, suggesting a premium valuation, while maintaining low price volatility with a modest 6.44% year-to-date return.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read more on Investing.com South Africa
